Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rFPV-HIV gag-pol + interferon-gamma
- Development stage
- Unknown
- Lead developer
- The Kirby Institute
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
rFPV-HIV gag-pol + interferon-gamma is a recombinant fowlpox virus (rFPV)-based therapeutic HIV vaccine candidate. It is engineered to express HIV-1 Gag and Pol antigens along with the cytokine interferon-gamma (IFN-γ), which serves as a molecular adjuvant to enhance the immune response. Developed by the Kirby Institute, this vaccine aims to stimulate or boost HIV-specific cellular immunity, particularly CD8+ cytotoxic T-cell responses, in individuals already infected with HIV-1. It was evaluated in the Phase I/II VIR-201 Extension Study (NCT00332930) to determine its safety and its ability to control viral replication following the interruption of antiretroviral therapy (ART). The inclusion of IFN-γ is intended to provide additional immunostimulatory signals to optimize the T-cell response compared to the Gag-Pol antigens alone.
- Other names
- HIV gag-pol antigens + interferon-gammarFPV-HIV gag-pol + IFN-gammarecombinant fowlpox virus-HIV gag-pol antigens + interferon-gamma
02
Targets
TCR-HIV-Pol-pMHC (T-cell receptor recognizing HIV-1 Pol-derived peptide–MHC complex)IFNGR1 (Interferon gamma receptor 1)T-cell receptor recognizing HIV-1 Gag-derived peptide–MHC complex
Beyond the preview
Go deeper on rFPV-HIV gag-pol + interferon-gamma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rFPV-HIV gag-pol + interferon-gamma.